Key Drivers
- Strong liquidity
- Large cash burn
- Severely negative margins
AIAI Summary
Pulse Biosciences has shifted from a speculative tech play to an event‑driven clinical‑development company whose valuation now prices successful pivotal readouts and early commercial translation—make trial execution (readouts, enrollment pace), cash‑runway management, and near‑term reimbursement signals your primary monitors because missed milestones or slower enrollment will likely force dilutive financings and cause outsized downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Large cash burn
- •Severely negative margins
Strong cash buffer and minimal debt mask severe operating losses, heavy cash burn and negative margins while the market appears to price in optimistic growth that current fundamentals don't support.
Price Behavior
Key Price Behavior Insights:
- •Medium-term downtrend
- •Short-term rebound
- •Elevated volatility
Over the last month the stock has a clear medium-term downtrend from the mid‑$20s creating resistance at $24–$26 while a sharp rebound since 2026‑03‑06 has pushed price above the 3‑week average with support at $18–$19 and elevated volatility, suggesting either tight, time‑limited exposure or waiting for a decisive breakout above the mid‑$20s.
Double-digit decline into early
Sentiment & News
Key News Insights:
- •Revenue beat
- •Clinical progress
- •Investor engagement
Pulse Biosciences beat revenue and narrowed its Q4 loss, highlighted procedural durability and first malignant-thyroid enrollments for its nPulse Vybrance system, and stepped up investor outreach amid routine executive equity moves.
The combination of encouraging clinical milestones and investor outreach should support sentiment and de-risk commercialization timelines, even as financials show only modest improvement
Similar Companies in Healthcare
Other companies in the same sector with AI ratings